Browsing Tag
AIM ImmunoTech Inc.
3 posts
Can Ampligen improve immunotherapy durability in recurrent ovarian cancer treatment?
Can AIM ImmunoTech Inc.’s Ampligen improve immunotherapy durability in ovarian cancer? Explore the Phase 2 data and industry impact.
Why pancreatic cancer clinicians and investors are closely watching AIM ImmunoTech’s next move
AIM ImmunoTech’s next Ampligen move could reshape pancreatic cancer treatment and investor sentiment. Find out what executives and markets are watching now.
How orphan drug status and patent protection shape Ampligen’s commercial and regulatory outlook
Discover how orphan drug status and long-dated patents could shape Ampligen’s regulatory path and commercial value in pancreatic cancer.